SPADA Draft Documents

cost effective. As described below, a cost-effective selection of inclusivity and exclusivity strains 124 for testing can be guided by in silico analyses and in silico PCR testing (described below).

125 126

127 Figure 2. Signature sequence identities of the target sequences of inclusivity/exclusivity panel 128 strains (SPADA panels) - Representative dataset depicting the heat map of amplicon percentage 129 matching in various whole genome sequences of bacterial strains used in inclusivity and 130 exclusivity testing of molecular assays. 131 132 Additional considerations with the availability of inclusivity/exclusivity panel reference 133 materials 134 A 2015 DoD moratorium on Biological Select Agents and Toxins (BSAT) work has 135 constrained the transfer of select agents between labs for testing during assay development (1). 136

7